Xenon Pharmaceuticals (NASDAQ:XENE) Posts Earnings Results

Xenon Pharmaceuticals (NASDAQ:XENE) released its quarterly earnings results on Monday. The biopharmaceutical company reported ($1.11) EPS for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.02, FiscalAI reports.

Here are the key takeaways from Xenon Pharmaceuticals’ conference call:

• Azetukalner’s focal-seizure NDA has been submitted, supported by two pivotal trials that Xenon says showed statistically significant seizure reductions across all tested doses and a consistent safety profile across more than 1,500 patient-years. The company is preparing for a potential U.S. launch.
• Xenon plans to start the X-FIRST study in Q1 2027 to assess azetukalner as a first add-on therapy earlier in the focal-seizure treatment journey, while its X-TOLE3 and X-ACKT Phase III studies continue. The company views these trials as opportunities to broaden the drug’s reach.
• Psychiatry remains uncertain: after neuropsychiatric adverse events led to a voluntary pause in new enrollment in MDD and bipolar-depression studies, Xenon expects X-NOVA2 results in December 2026 and plans to review them with the DSMB and FDA before deciding next steps.
• Phase I results for pain candidates XEN1701 (NaV1.7) and XEN1120 (Kv7) supported moving both into acute-pain Phase II proof-of-concept studies, which Xenon expects to initiate in the first half of 2027. The company reported generally favorable tolerability, though efficacy in people with pain has not yet been established.
• Xenon reported $1.2 billion in cash, cash equivalents and marketable securities, which it expects to fund operations into 2029, including the azetukalner launch preparations and advancement of its pipeline.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ:XENE opened at $41.39 on Wednesday. Xenon Pharmaceuticals has a 1 year low of $33.38 and a 1 year high of $72.66. The business’s 50-day moving average is $42.27 and its 200-day moving average is $52.14. The company has a market capitalization of $4.00 billion, a price-to-earnings ratio of -8.81 and a beta of 0.11.

Analyst Ratings Changes

Several research firms have issued reports on XENE. Guggenheim initiated coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, October 6th. They set a “buy” rating and a $73.00 price target for the company. Jefferies Financial Group restated a “buy” rating and issued a $90.00 price target on shares of Xenon Pharmaceuticals in a research report on Monday, September 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Friday, October 2nd. Wells Fargo & Company reduced their price objective on shares of Xenon Pharmaceuticals from $69.00 to $64.00 and set an “overweight” rating on the stock in a research note on Friday, September 18th. Finally, Royal Bank Of Canada decreased their price objective on shares of Xenon Pharmaceuticals from $81.00 to $70.00 and set an “outperform” rating for the company in a research report on Friday, September 18th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Xenon Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $71.31.

Insider Buying and Selling

In other Xenon Pharmaceuticals news, insider Christopher Kenney sold 7,068 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $60.25, for a total value of $425,847.00. Following the completion of the sale, the insider directly owned 2 shares in the company, valued at approximately $120.50. The trade was a 99.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ian Mortimer purchased 30,000 shares of the company’s stock in a transaction on Wednesday, September 30th. The stock was acquired at an average cost of $37.38 per share, for a total transaction of $1,121,400.00. Following the completion of the purchase, the chief executive officer owned 49,923 shares of the company’s stock, valued at approximately $1,866,121.74. This trade represents a 150.58% increase in their position. The SEC filing for this purchase provides additional information. 2.91% of the stock is currently owned by insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for neurological disorders. The company’s research emphasizes ion channels, proteins that help regulate the electrical activity of nerve cells. Its lead program is azetukalner, formerly known as XEN1101, an oral Kv7 potassium-channel opener being developed for seizure disorders, including focal epilepsy. Xenon is also advancing other drug candidates aimed at neurological conditions. Founded in 1996, Xenon is headquartered in Burnaby, British Columbia, and conducts drug development activities in North America.